Bernstein Upgrades Amgen (AMGN) to Outperform
More News related to AMGN
- Amgen Highlights Data to be Presented at ASH
- Beacon Equity Issues Technical Trading Overview for NexMed Inc.
- Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
- Amgen to Present at Lazard Capital Healthcare Conference
- Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
More News related to Upgrades
- Fed banks said economic conditions 'improved modestly'
- NIH Approves 13 Stem-Cell Lines for Research; Watch STEM, ASTM, PSTI, CYTX, GERN on the News
- Goldman Issues 'Top Trades of 2010': Sees 2010, 2011 'Rather Strong Years', Gives Global, US, Euro, BRIC GDP Estimates
- Tiger's Days as Advertising King are Over
- Jarden (JAH) Offers Variety of Products and Good Earnings Potential -Cramer
Sanford C. Bernstein upgrades Amgen (Nasdaq: AMGN) from Market Perform to Outperform.
For more analyst ratings on AMGN click here.
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
Related Categories
UpgradesStocks Mentioned
+0.42Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
